DDAVP

LOE Approaching

desmopressin acetate

NDAINJECTIONINJECTABLEPriority Review

Approved

Mar 1984

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

2

Mechanism of Action

Willebrand's disease Type I. The antidiuretic effects of desmopressin acetate are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin acetate is a replacement hormone for antidiuretic…

Indications (7)

nephrogenic diabetes insipidus there is evidence of an abnormal molecular form of factor VIII antigen severe von Willebrand's disease (Type I)bleeding with episodes of spontaneous traumatic injuries such intramuscular hematomas mucosal bleeding

Clinical Trials (2)

NCT01576900N/ACompleted

The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia

Started Apr 2012

124 enrolled

Nocturia

NCT00835211Phase 1Completed

Desmopressin Acetate 0.2 mg Tablets, Fasting

Started Jul 2003

48 enrolled

Healthy

Company

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers